Product Description
IMX-111 is a preclinical drug candidate from Immix Biopharma for the treatment of colorectal cancer. (Sourced from: https://www.immixbio.com/pipeline/)
Mechanisms of Action: GLUT1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immix Biopharma
Company Location: LOS ANGELES CA 90064
Company CEO: Ilya Rachman
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|